3[1]De Pierre A. Overview of the role for neoadjuvant therapy for early-stage non-small cell lung cancer. Lung Cancer,2000,29(Suppl 2)∶124-125.
4[2]Albain KS, Pass HI. Induction therapy before surgery for non-small cell lung cancer. Lung Cancer,2000,29(Suppl 2)∶168-171.
5[3]De Pierre A, Milleron B, Chevret S, et al. French phase Ⅲ trial of preoperative chemotherapy (PCT) in resectable stage Ⅰ (except T1N0), Ⅱ, Ⅲa non-small cell lung cancer (NSCLC). Lung Cancer,2000,29(Suppl 1)∶91.
6[4]Splinter T, Groen H, Smit E, et al. Randomized multicenter phase Ⅱ study of chemotherapy followed by surgery versus surgery alone in stage Ⅰand Ⅱ non-small cell lung cancer (NSCLC). Lung Cancer,2000,29(Suppl 1)∶90.
7[5]Eberhardt W, Korfee S, Wagner H, et al. "Minimal N2-disease”(operable) stage ⅢA non-small cell lung cancer: Prospectively randomized multicenter German phase-Ⅲ-trial of surgery (S) followed by adjuvant radiotherapy (RTx) versus "Trimodality treatment”-Early results of feasibility and toxicity in this setting. Lung Cancer,2000,29(Suppl 1)∶95-96.
8[6]Mattson K, Ten Valde G, Krofta K, et al. Early results of an international phase Ⅲ study evaluating Taxotere as neo-adjuvant therapy for radically-treatable stage Ⅲ NSCLC. Lung Cancer,2000,29(Suppl 1)∶90.
9[7]O'Rourke N, Armour A. Neo-adjuvant chemotherapy in stage Ⅲ NSCLC in the West of Scotland improves the potential for cure. Lung Cancer,2000,29(Suppl 1)∶107.
10[8]Saito Y, Minami K, Kobayashi M, et al. Ten years' experience of induction therapy for locally advanced NSCLC; a single institution study. Lung Cancer,2000,29(Suppl 1)∶89-90.
